Dr. Ready’s European business income grew 15% year-on-year
Dr. Reddy’s (EBITDA) margin for the fourth quarter stood at 24% per cent, against an estimate of 22.5%.
New Delhi. Dr. Reddy’s (DR REDDYS) has released the results for the quarter ended 31 March 2021 of the financial year 200-21. During this period, the company’s income increased from Rs 4432 crore in the fourth quarter of last year to Rs 4728 crore. At the same time, the company has announced a dividend of Rs 25 per equity share for the shareholders. In the fourth quarter, the company’s profit fell 27.6 percent year-on-year to Rs 560 crore. It was estimated to be at 654 crore rupees. Explain that in the fourth quarter of last year, the company had Rs 764 crore. However, in the fourth quarter it was estimated that the company’s income would be Rs 4822 crore. Read also: Delay for final settlement of LTC, now bills can be submitted by this date EBITDA stood at Rs.1133 crores against the estimate of Rs.1099 crores.The EBITDA of the company in the January-March quarter has been Rs 1133 crore against an estimate of Rs 1099 crore. The company’s EBITDA stood at Rs 1,001 crore in the fourth quarter of last year. EBITDA margin for the fourth quarter stood at 24% per cent, against an estimate of 22.5%. Explain that the company’s margin was at 22.6% in the fourth quarter of last year. Read also: This bank made changes in FD rates, you can also avail higher interest rate, know everything The company’s North America business income plummeted 3% year-on-year.
Dr. Reddy’s European business income grew 15% year-on-year. Whereas, the company’s North America business income declined 3% year-on-year. At the same time, PSAI business has seen a 10% boom. Indian business income of the company grew by 23% on an annual basis during this period. At the same time, the income of global generics business grew by 6% on an annual basis. ALSO READ: Success Story: TPA left business to take care of parents, now has a portfolio of 3000 crores Dr. Reddy Lab will make Sputnik vaccine in the country In addition to the India biotech cocaine and Oxford-AstraZenec’s covishield in the country, now Russia’s Sputnik V vaccine will also be installed. It will be available in the market from next week. However, this vaccine will be slightly more expensive than the pre-existing vaccine. The price of one dose of Sputnik-V will be Rs 995.40. It is being told that Sputnik V will be manufactured in India, so its price has been kept. Dr. Reddy’s Lab, the company that imported the company into India, gave this information. The company said that this vaccine was approved by the Central Drugs Laboratories on Thursday.